scispace - formally typeset
D

David C. Currow

Researcher at University of Technology, Sydney

Publications -  884
Citations -  26604

David C. Currow is an academic researcher from University of Technology, Sydney. The author has contributed to research in topics: Palliative care & Population. The author has an hindex of 68, co-authored 807 publications receiving 21352 citations. Previous affiliations of David C. Currow include Dartmouth–Hitchcock Medical Center & Nepean Hospital.

Papers
More filters
Journal ArticleDOI

Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

Claudia Allemani, +594 more
- 17 Mar 2018 - 
TL;DR: For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden, while for many cancers, Denmark is closing the survival gap with the other Nordic countries.
Journal ArticleDOI

Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study

TL;DR: Progress in cancer control over the study period was evident for stomach, colon, lung (in males), and ovarian cancer, and the impact of comorbidity are likely the main determinants of patient outcomes.
Journal ArticleDOI

Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea

TL;DR: Sustained release, oral morphine at low dosage provides significant symptomatic improvement in refractory dyspnoea in the community setting.
Journal ArticleDOI

A systematic review of prognostic/end-of-life communication with adults in the advanced stages of a life-limiting illness: patient/caregiver preferences for the content, style, and timing of information

TL;DR: Although there were individual differences, patients/caregivers in general had high levels of information need at all stages of the disease process regarding the illness itself, likely future symptoms and their management, and life expectancy and information about clinical treatment options.
Journal ArticleDOI

Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials

TL;DR: Anamorelin significantly increased lean body mass, but not handgrip, strength in patients with advanced non-small-cell lung cancer and cachexia, considering the unmet medical need for safe and effective treatments for cachexia.